Abstract | BACKGROUND: PATIENTS AND METHODS: Patients with pediatric sarcoma subtypes, refractory to or relapsed after at least one prior induction chemotherapy, inoperable, ECOG PS 0-2, with measurable, progressive disease (PD), adequate organ functions, who have been treated with TC combination were retrospectively analysed within the AIO and SAREZ/BMBF network. RESULTS: Thirty-nine patients, median age 28 years (18-58), 14 females, 25 males, have been identified. All patients had received induction treatment according to (inter)national study protocols. Second-line TC was applied in 33 patients (≥3rd-line in 6 patients). Twenty-three patients had refractory disease (evidence of PD during induction chemotherapy); 8 patients experienced an early relapse within 6 months as well as 8 patients after more than 24 months (late relapse). A median of 3 cycles (range, 1-6) had been applied and antitumor activity was: CR 2.6 %, PR 7.9 %, and disease stabilisation (SD) 26.3 %. PR lasted 32.8 months and median duration in patients with SD was 5 months (range, 2.0-14.7). The 3/6-months progression-free rates were 43.2 and 18.9 %. CONCLUSIONS: Limited activity was seen in adult pts with refractory or relapsed pediatric-type sarcomas with the regimen which has proven activity in pediatric patients. Adults with refractory small cell sarcoma appear to have a similar dismal outcome as seen in pts with common adult-type histologies; however, a subset of patients has achieved long-lasting remissions on TC resulting in long-term survival.
|
Authors | Jörg Thomas Hartmann, R D Issels, K San Nicolo, V Grünwald, B Hertenstein, E Papesch, S Krause, I Sturm |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 33
Issue 5
Pg. 1115-22
(Oct 2015)
ISSN: 1573-0646 [Electronic] United States |
PMID | 26163339
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Topotecan
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cyclophosphamide
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Prognosis
- Retrospective Studies
- Sarcoma
(drug therapy, mortality)
- Survival Analysis
- Topotecan
(therapeutic use)
- Young Adult
|